Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Oncopeptides AB
Industry Sector: HealthTechnology
CEO: Sofia Heigis
Number Of Employees: 80
Enterprise Value: $24,763,557
PE Ratio: -1.01
Exchange/Ticker 1: SSE:ONCO
Exchange/Ticker 2: N/A
Latest Market Cap: $32,519,340
BioCentury | Sep 17, 2024
Deals
Pair of radiopharma deals sees Sanofi dive into 212Pb as ITM gets another 177Lu program
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
BioCentury | Oct 13, 2023
Management Tracks
CSO Lawson succeeding CEO Öhrström at VarmX
Plus: New CMO at Glycomine and updates from Halo, Roth, Sound Bioventures and the Global Virus Network
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
BioCentury | Jun 15, 2023
Management Tracks
Moderna’s Burton returns to Amgen
Plus: Allogene falls on Schmidt’s departure and updates from bioMerieux, Carisma, Spero and Oncopeptides
BioCentury | Mar 1, 2023
Management Tracks
C4’s Adam Crystal to head R&D at Tango
Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more
BioCentury | Jan 12, 2023
Management Tracks
Azafaros hires Freitag, promotes Landskroner
Plus: KemPharm promotes Guenther and Mickle, and updates from
BioCentury | Jan 5, 2023
Management Tracks
Sanofi’s Sarchi heads to Replimune
Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more
BioCentury | Dec 8, 2022
Product Development
Dec. 7 Quick Takes: Strong Enhertu data continue with DESTINY-Breast03 readout at SABCS
Plus: EC calls for Illumina to unwind Grail acquisition and updates from Vor, Paragon’s Apogee, Oncopeptides and more
BioCentury | Sep 23, 2022
Regulation
ODAC signals Oncopeptides’ drug heading for accelerated approval ‘off-ramp’
Committee’s vote against Pepaxto, Spectrum’s Pozenveo follows Pazdur’s call for ‘equal emphasis’ of the on and off ramps of accelerated approval
BioCentury | Sep 20, 2022
Regulation
FDA sets high benefit-risk bar ahead of Oncopeptides, Spectrum panels
Pair of biotechs’ shares sink as briefing documents show agency reviewers’ lack of enthusiasm for data packages
Items per page:
1 - 10 of 44